Surmodics (NASDAQ:SRDX – Get Free Report) and Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.
Volatility & Risk
Surmodics has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Guided Therapeutics has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for Surmodics and Guided Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Surmodics | 1 | 3 | 1 | 0 | 2.00 |
| Guided Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Profitability
This table compares Surmodics and Guided Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Surmodics | -14.59% | -2.99% | -1.99% |
| Guided Therapeutics | N/A | N/A | -219.85% |
Insider and Institutional Ownership
96.6% of Surmodics shares are held by institutional investors. Comparatively, 9.7% of Guided Therapeutics shares are held by institutional investors. 8.9% of Surmodics shares are held by company insiders. Comparatively, 66.8% of Guided Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Surmodics and Guided Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Surmodics | $126.08 million | 3.12 | -$11.54 million | ($1.23) | -22.36 |
| Guided Therapeutics | $10,000.00 | 1,922.80 | -$2.42 million | ($0.05) | -4.60 |
Guided Therapeutics has lower revenue, but higher earnings than Surmodics. Surmodics is trading at a lower price-to-earnings ratio than Guided Therapeutics, indicating that it is currently the more affordable of the two stocks.
About Surmodics
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
About Guided Therapeutics
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.
Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter.
